+357 96 030922
info@marketpublishers.com

Gene Modifying Immunotherapy for Blood Cancer Market, Global Outlook and Forecast 2022-2028

https://marketpublishers.com/r/G7E07022360FEN.html
Date: February 2022
Pages: 60
Price: US$ 3,250.00 (Single User License)
ID: G7E07022360FEN

Abstracts

Genetic modification immunotherapy for blood cancer is a technique that involves genetic modification of immune system T cells.It allows T cells to recognize weakly expressed antigens in the blood or other organs of the body, such as tumor cells.This form of immunotherapy can be divided into two types: one in which the patient receives genetically modified immune cells from a donor, and the other in which the patient's own immune cells are removed, genetically modified and then given back to the patient.CAR T cell therapy involves genetically altering immune system T cells to produce a protein called CAR or chimeric antigen receptor protein, which helps T cells attach to specific proteins on the surface of tumor cells, making it easier for them to recognize cancer cells.

This report contains market size and forecasts of Gene Modifying Immunotherapy for Blood Cancer in Global, including the following market information:

Global Gene Modifying Immunotherapy for Blood Cancer Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Gene Modifying Immunotherapy for Blood Cancer market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

+357 96 030922
info@marketpublishers.com

CAR T-cell Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Gene Modifying Immunotherapy for Blood Cancer include Novartis, Kite Pharma, Juno Therapeutics, Cellectis, Ziopharm Oncology, Celyad, Bluebird Bio, Bellicum Pharmaceuticals and Mustang Bio. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Gene Modifying Immunotherapy for Blood Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Gene Modifying Immunotherapy for Blood Cancer Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Gene Modifying Immunotherapy for Blood Cancer Market Segment Percentages, by Type, 2021 (%)

CAR T-cell Therapy

TCR T-cell Therapy

Global Gene Modifying Immunotherapy for Blood Cancer Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Gene Modifying Immunotherapy for Blood Cancer Market Segment Percentages, by Application, 2021 (%)

Acute Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

B Cell Lymphoma

Multiple Myeloma

+357 96 030922
info@marketpublishers.com

Other

Global Gene Modifying Immunotherapy for Blood Cancer Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Gene Modifying Immunotherapy for Blood Cancer Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

+357 96 030922
info@marketpublishers.com

- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia

South America

- Brazil
- Argentina
- Rest of South America

Middle East & Africa

- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Gene Modifying Immunotherapy for Blood Cancer revenues in global market, 2017-2022 (estimated), ($ millions)

+357 96 030922
info@marketpublishers.com

Key companies Gene Modifying Immunotherapy for Blood Cancer revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Novartis

Kite Pharma

Juno Therapeutics

Cellectis

Ziopharm Oncology

Celyad

Bluebird Bio

Bellicum Pharmaceuticals

Mustang Bio

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

6 SIGHTS BY REGION

+357 96 030922
info@marketpublishers.com

7 PLAYERS PROFILES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Gene Modifying Immunotherapy for Blood Cancer Market, Global Outlook and Forecast 2022-2028

Product link: https://marketpublishers.com/r/G7E07022360FEN.html

Price: US$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G7E07022360FEN.html